InflaRx N.V. (NASDAQ:IFRX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of InflaRx N.V. (NASDAQ:IFRX) have earned an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $7.00.

A number of research analysts recently issued reports on the stock. Guggenheim reiterated a “buy” rating and issued a $14.00 price target on shares of InflaRx in a report on Tuesday, April 21st. Weiss Ratings restated a “sell (d-)” rating on shares of InflaRx in a report on Friday, March 27th. Cantor Fitzgerald increased their price target on shares of InflaRx from $2.00 to $4.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Oppenheimer initiated coverage on shares of InflaRx in a research note on Friday, April 24th. They issued an “outperform” rating and a $5.00 price target for the company. Finally, Wall Street Zen raised shares of InflaRx from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th.

InflaRx Stock Performance

Shares of InflaRx stock opened at $1.60 on Wednesday. The firm has a market cap of $115.66 million, a P/E ratio of -2.25 and a beta of 2.42. InflaRx has a twelve month low of $0.74 and a twelve month high of $2.95. The firm’s 50-day simple moving average is $1.88 and its 200-day simple moving average is $1.30.

InflaRx (NASDAQ:IFRX) last announced its earnings results on Thursday, May 7th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.08. On average, equities analysts forecast that InflaRx will post -0.4 earnings per share for the current fiscal year.

Institutional Investors Weigh In On InflaRx

A number of hedge funds have recently made changes to their positions in IFRX. Cubist Systematic Strategies LLC boosted its position in InflaRx by 33.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after buying an additional 7,616 shares during the period. Boothbay Fund Management LLC raised its stake in InflaRx by 10.8% during the third quarter. Boothbay Fund Management LLC now owns 175,114 shares of the company’s stock worth $235,000 after buying an additional 17,056 shares during the last quarter. Concurrent Investment Advisors LLC lifted its position in shares of InflaRx by 56.9% during the 4th quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock valued at $53,000 after acquiring an additional 19,200 shares during the period. Eversept Partners LP lifted its position in shares of InflaRx by 1.5% during the 4th quarter. Eversept Partners LP now owns 1,757,312 shares of the company’s stock valued at $1,775,000 after acquiring an additional 26,677 shares during the period. Finally, Squarepoint Ops LLC lifted its position in shares of InflaRx by 29.1% during the 3rd quarter. Squarepoint Ops LLC now owns 188,523 shares of the company’s stock valued at $253,000 after acquiring an additional 42,489 shares during the period. 42.39% of the stock is currently owned by institutional investors and hedge funds.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.